NT-I7 (Efineptakin alfa)

What is NT-I7 (Efineptakin alfa)?

NT-I7, international nonproprietary name efineptakin alfa, is a long-acting form of interleukin-7 developed by NeoImmuneTech. It originated at the Korean biotech Genexine, which is why it also appears in the literature as GX-I7, and it is constructed by genetically fusing two N-terminally stabilised IL-7 moieties to a hybrid Fc scaffold — hence the designation rhIL-7-hyFc. The Fc fusion extends IL-7's native half-life from minutes-to-hours into a long-acting profile supporting intramuscular dosing at intervals of weeks. A note on classification, since this site is a peptide reference. NT-I7 is not a peptide by any strict definition. Mature IL-7 is a 152-amino-acid cytokine of roughly 17 kDa, and NT-I7 presents two copies of it on a dimeric Fc scaffold, giving a glycosylated molecule on the order of 80 kDa — an order of magnitude beyond even permissive peptide definitions. It is a recombinant cytokine-Fc fusion protein biologic. It is covered here for the same reason romiplostim is, as a therapeutically important Fc-fusion that people searching thymic and immune peptides will look for, and with the same commitment to naming what it actually is rather than filing it under a category it does not belong to. The genuine peptides in this space — thymosin alpha-1 at 28 residues, thymalin, thymopentin — are different molecules doing different things on an overlapping axis. What NT-I7 does is well established: it expands peripheral CD4+ and CD8+ T cells, including in lymphopenic patients, with a clinical record spanning more than 800 subjects across 15 studies. What it has not yet been shown to do is anything in the indications it was most recently licensed for. On 19 August 2026 NeoImmuneTech licensed exclusive Americas and Europe rights for certain thymus-related indications to Tolerance Bio, in exchange for a 4% equity stake plus up to $260 million in development and sales milestones and tiered royalties — retaining all other territories and its core immuno-oncology programs. Tolerance Bio has named HIV immunological non-response as its lead indication. No such trial is registered.

What NT-I7 (Efineptakin alfa) Is Investigated For

The gap between what NT-I7 has demonstrated and what it is currently being marketed toward is the most important thing to understand about this molecule. What it has demonstrated, in real journals with real human data, is T-cell expansion. Butt and colleagues reported in Clinical Cancer Research in 2026 that NT-I7 increases lymphocyte counts and induces CD8+ T-cell clonotype expansion in newly diagnosed high-grade glioma. Campian and colleagues published a Phase 1 in severe treatment-related lymphopenia after standard radiation and temozolomide. Ramaswami and colleagues reported a Phase 1 in Kaposi sarcoma in the Journal for ImmunoTherapy of Cancer. Kim and colleagues showed in the British Journal of Cancer that GX-I7 safely increased peripheral CD8+ and CD4+ T cells and tumour-infiltrating lymphocytes in advanced solid tumours. A population pharmacokinetic and pharmacodynamic model has been published to support dosing. Preclinically, the molecule enhances CAR-T expansion and persistence, improves checkpoint-inhibitor efficacy in humanised models, and restores T-cell reconstitution in a humanised mouse model of lymphopenia. That is a coherent and substantial evidence base for one thing: making T cells. What has not been demonstrated is any of the indications the August 2026 Tolerance Bio deal was announced around. Thymic function preservation, age-related immunosenescence, and HIV immunological non-response have no published NT-I7 human data and no registered NT-I7 trials. The closest existing study is NCT05600920, a Phase 1/2 in idiopathic CD4 lymphopenia sponsored by NIAID — a genuinely relevant analogue, but idiopathic CD4 lymphopenia is not HIV, and describing it as an HIV trial would be wrong. Historical IL-7 work in HIV and post-transplant immune reconstitution used Cytheris's CYT107, a different molecule, and should not be attributed to NT-I7. Two further caveats belong in any honest assessment. First, roughly eleven of the twenty-five-odd registered NT-I7 trials were terminated or withdrawn, including combinations with atezolizumab and nivolumab and two COVID-19 studies — a high attrition rate that suggests the oncology thesis has been harder to land than the T-cell expansion data alone would imply. Second, the deal structure is worth reading carefully: NeoImmuneTech received equity and contingent milestones rather than cash upfront, and retained its core oncology programs. That reads as divesting a non-core indication set for optionality, not as external validation of the thymic hypothesis.

History & Discovery

Interleukin-7 has been a frustrating drug target for as long as its importance has been understood. It was identified in the late 1980s as a stromal-derived factor required for B- and T-lymphocyte development, and its non-redundancy was established beyond argument when loss-of-function mutations in IL7R were found to cause a form of severe combined immunodeficiency. If a cytokine is required to build T cells, giving it to people who lack T cells is an obvious idea. The obstacle was pharmacokinetic: native IL-7 is consumed by its own receptor and cleared renally within minutes to hours, so sustaining a therapeutic level requires impractical dosing. The first serious clinical attempt came from Cytheris, a French biotech that developed recombinant human IL-7 as CYT107 and tested it through the 2000s and early 2010s in HIV, post-haematopoietic-stem-cell-transplant immune reconstitution, and elsewhere. That programme generated the IL-7-in-HIV literature that is still cited today — and it is important not to attribute it to NT-I7, which is a structurally different molecule from a different company. The long-acting approach came out of Genexine in South Korea, which fused IL-7 to its proprietary hybrid Fc (hyFc) platform, producing rhIL-7-hyFc — designated GX-I7 in the Genexine literature. NeoImmuneTech was subsequently spun out to develop the asset internationally, and the molecule received the international nonproprietary name efineptakin alfa. Early trials from 2016 onward ran in healthy volunteers, HPV-infected women, and then across solid tumours and glioblastoma, establishing the pharmacodynamic signature that defines the molecule: reliable, dose-related expansion of CD4+ and CD8+ T cells from a single intramuscular injection. The strategic bet through the late 2010s and early 2020s was immuno-oncology, on the reasoning that checkpoint inhibitors and CAR-T therapies need T cells to work with and that lymphopenic patients respond poorly. NT-I7 was tested in combination with pembrolizumab across multiple trials, with nivolumab in gastric and oesophageal cancer, with atezolizumab in non-small-cell lung cancer and high-risk skin cancers, and following CD19- and BCMA-directed CAR-T. The preclinical support was genuinely strong — Kim and colleagues published enhancement of CAR-T expansion and persistence in Nature Communications in 2022. The clinical execution was harder: roughly eleven of approximately twenty-five registered trials were terminated or withdrawn, including the atezolizumab and nivolumab combinations and two COVID-19 studies begun during the pandemic. What survived and read out positively was largely the lymphopenia work — Campian and colleagues in treatment-related lymphopenia after chemoradiation, Butt and colleagues showing clonotype expansion in high-grade glioma, Kim and colleagues showing increased tumour-infiltrating lymphocytes in solid tumours. The most recent chapter is a repositioning. On 19 August 2026 NeoImmuneTech licensed exclusive Americas and Europe rights, limited to certain thymus-related indications, to Tolerance Bio — a small US company led by Francisco Leon and backed by Columbus Venture Partners and others from a $20.2 million seed round. The consideration was a 4% equity stake plus up to $260 million in development and sales milestones and tiered royalties; NeoImmuneTech retained all other territories and its core immuno-oncology programs. Tolerance Bio framed the deal around thymic function and immune resilience and named HIV immunological non-response as an initial indication to be evaluated. The honest reading of that transaction is that a company with a molecule whose oncology thesis had proven difficult monetised a non-core indication set for equity and contingent value, rather than that an external party validated a new mechanism. The thymic and immunosenescence framing has no NT-I7 human data behind it and no registered trials. What NT-I7 unambiguously has is roughly twenty peer-reviewed publications, several with human data in real journals, and a demonstrated ability to make T cells in people who need them — which is a real asset in search of the right indication.

How It Works

Interleukin-7 is the signal your body uses to build and maintain T cells, the white blood cells that recognise infections and cancer. It works in two places: inside the thymus, where new T cells are made, and out in the bloodstream, where it keeps existing T cells alive. People with too few T cells — after chemotherapy or radiation, after certain cancer treatments, or from conditions that suppress the immune system — are vulnerable, and giving them more IL-7 should help. The problem is that natural IL-7 disappears from the blood within hours. NT-I7 fixes this by attaching two copies of IL-7 to a piece of antibody scaffold, which slows clearance enough that one injection lasts weeks. In people, it does raise T-cell counts, consistently. Whether higher counts actually make patients do better is the part still being worked out.

Interleukin-7 is a 152-amino-acid cytokine produced principally by thymic and bone marrow stromal cells and by lymph node fibroblastic reticular cells. It signals through a heterodimeric receptor comprising IL-7 receptor alpha (IL-7Rα, CD127) paired with the common gamma chain (γc, CD132), activating JAK1 and JAK3 with downstream STAT5 phosphorylation alongside PI3K–Akt and MEK–ERK arms. The functional output is survival and proliferation: IL-7 upregulates anti-apoptotic Bcl-2 family members and drives cell-cycle entry in developing and mature T cells. IL-7's role is non-redundant. In the thymus it is required for T-cell development, supporting survival and proliferation of double-negative thymocytes and V(D)J recombination; loss-of-function mutations in IL7R cause a form of severe combined immunodeficiency. In the periphery it maintains the naive T-cell pool and supports memory CD8+ T-cell homeostasis. Notably, IL-7Rα is downregulated on activated effector T cells and on regulatory T cells, which means exogenous IL-7 preferentially expands naive and memory conventional T cells rather than Tregs — a favourable selectivity for immuno-oncology and for immune reconstitution, and a meaningful contrast with IL-2, whose Treg expansion has complicated its therapeutic use for decades. The pharmacokinetic problem is severe: native IL-7 has a circulating half-life measured in minutes to hours, driven by receptor-mediated consumption and renal clearance. NT-I7 addresses this by genetic fusion. Two IL-7 moieties, stabilised by N-terminal engineering, are fused to a hybrid Fc (hyFc) platform, producing a homodimeric Fc-fusion protein. The Fc domain extends half-life through neonatal Fc receptor (FcRn)-mediated recycling — the same mechanism that gives IgG its multi-week persistence — while increasing hydrodynamic radius above the renal filtration threshold. The resulting molecule is roughly 80 kDa glycosylated and supports intramuscular dosing at intervals of weeks; the Phase 1/2 study in idiopathic CD4 lymphopenia, for instance, uses three intramuscular doses at twelve-week intervals. A published population pharmacokinetic and pharmacodynamic model (Park et al., Drug Des Devel Ther 2025) formalises the exposure-response relationship to support dosing regimen selection. In humans the pharmacodynamic effect is consistent and dose-related: increased absolute lymphocyte count, expansion of both CD4+ and CD8+ compartments, and — in the glioma work of Butt and colleagues — CD8+ T-cell clonotype expansion, indicating that the expanded cells include newly recruited clones rather than simply proliferation of what was already dominant. Kim and colleagues demonstrated increased tumour-infiltrating lymphocytes as well as peripheral counts. Kim and colleagues separately showed in Blood Advances that a single administration induces long-lasting T-cell expansion with maintained effector function, which is the pharmacological property that makes infrequent dosing viable. The preclinical rationale for combination is strong and specific. rhIL-7-hyFc enhances CAR-T cell expansion, persistence, and antitumour activity (Kim et al., Nat Commun 2022), improves anti-PD-1 efficacy in autologous humanised melanoma models, and expands virus-specific stem-like CD8+ T cells in chronic viral infection (Lee et al., Cell Rep 2026) — the last being the closest published mechanistic support for the HIV immunological non-response hypothesis, though it remains a mouse result. Pérez-Díez and colleagues showed restoration of T-cell reconstitution in a humanised mouse model of lymphopenia (J Allergy Clin Immunol 2026).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about NT-I7 (Efineptakin alfa):

• 01The largest gap is the mismatch between evidence and positioning: there are no published human data and no registered trials for NT-I7 in thymic regeneration, age-related immunosenescence, healthy aging, or HIV immunological non-response — precisely the indications the August 2026 licence was announced around.
• 02Whether expanding peripheral T-cell counts improves clinical outcomes. The pharmacodynamics are excellent and consistently reproduced; the outcome data are thin, and roughly eleven of twenty-five registered trials were terminated or withdrawn, which is the strongest available signal that this translation has been difficult.
• 03Whether NT-I7 affects thymic function itself or only peripheral T-cell homeostasis. The two are mechanistically distinct — IL-7 acts in both compartments — and the entire thymic-indication thesis depends on the former, which has not been demonstrated in humans.
• 04HIV immunological non-response specifically. The existing IL-7-in-HIV literature used Cytheris's CYT107, a different molecule; the closest NT-I7 evidence is a mouse chronic-viral-infection model showing expansion of virus-specific stem-like CD8 T cells.
• 05Long-term safety of repeated cytokine dosing, including autoimmune risk and any risk of promoting T-cell malignancy — mechanistically serious given that IL-7R pathway activation is implicated in T-cell acute lymphoblastic leukaemia.
• 06Immunogenicity across extended exposure — anti-drug antibodies against an Fc-fusion cytokine could reduce exposure or, more concerningly, cross-react with endogenous IL-7.
• 07Optimal sequencing with lymphodepleting chemotherapy and CAR-T therapy, where the preclinical case is strong but the clinical protocols are still being established.
• 08Why the checkpoint-inhibitor combination programme largely stopped. The terminations were not accompanied by published efficacy or safety analyses, leaving the field without a clear account of what did not work.

Forms & Administration

NT-I7 is administered by intramuscular injection at intervals of weeks — the NIAID Phase 1/2 study in idiopathic CD4 lymphopenia, for example, gives three doses at twelve-week intervals. Some earlier trials used other schedules, and dosing across the program has been informed by a published population pharmacokinetic and pharmacodynamic model. It is supplied only as investigational product to registered clinical trial sites; there is no approved formulation, no commercial product, and no compounding pathway. Because NT-I7 is a glycosylated recombinant Fc-fusion protein of roughly 80 kDa produced in mammalian cell culture, it cannot be synthesised by the solid-phase peptide chemistry that supplies the research-chemical market, and any product advertised as NT-I7 outside a clinical trial is implausible on manufacturing grounds alone. Administration requires clinical supervision appropriate to cytokine therapy, including monitoring of lymphocyte subsets.

Common Questions

Who NT-I7 (Efineptakin alfa) Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies have been published, and as a recombinant Fc-fusion protein NT-I7 is cleared by receptor-mediated consumption, proteolysis, and FcRn recycling rather than by hepatic cytochrome P450 metabolism, so classical pharmacokinetic interactions are not expected. The relevant interactions are immunological. Immunosuppressants are the most consequential. Corticosteroids, calcineurin inhibitors, antimetabolites, and lymphodepleting agents act directly against NT-I7's mechanism. This matters practically because corticosteroids are widely used in the exact populations NT-I7 has been tested in — glioma patients on dexamethasone, for instance — and because lymphodepleting chemotherapy is standard before CAR-T therapy, where the sequencing relative to NT-I7 is part of what the combination trials are working out. Checkpoint inhibitors are the intended combination rather than an interaction to avoid, and much of the clinical program has paired NT-I7 with pembrolizumab or nivolumab. The mechanistic logic is complementary — NT-I7 supplies T cells, checkpoint blockade removes the brake on them — but combined immune activation raises the theoretical possibility of amplified immune-related adverse events, and the high termination rate across those combination trials means the tolerability of the pairing is less well established than the preclinical rationale would suggest. Live vaccines warrant caution on general principles in any patient receiving an immunomodulatory biologic, though the direction of effect here is immune enhancement rather than suppression, so the concern is atypical. As an Fc-fusion protein, NT-I7 also raises immunogenicity considerations that a small synthetic peptide would not — anti-drug antibodies could in principle reduce exposure or cross-react with endogenous IL-7, and this is monitored in trials rather than being a drug interaction in the conventional sense.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions